NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

BOSTON, Feb 26 (Reuters) - King Pharmaceuticals Inc posted a fourth-quarter loss on Thursday as sales of its blood pressure drug fell and it took an acquisition-related charge. The company reported a ...

BRISTOL, Tenn. and SAN MATEO, Calif., Dec. 27, 2010 (GLOBE NEWSWIRE) -- King Pharmaceuticals ®, Inc. (NYSE:KG) and Pain Therapeutics ®, Inc. (Nasdaq:PTIE) today announced that King has resubmitted a ...

King Pharmaceuticals, Inc. (NYSE: KG) earned $0.15 per share in the three months that ended on 30 June 2009, down from $0.17 per share in the second quarter of last year. Please click here to see a ...

CHICAGO, Nov 30 (Reuters) - King Pharmaceuticals Inc option volume surged on Friday fueled by speculation that the drug maker may be acquired, according to several options analysts. Pfizer Inc , the ...

Pfizer Inc.'s $3.6 billion purchase of King Pharmaceuticals Inc. adds abuse-resistant narcotics to help the drugmaker expand its share of the $22 billion market for painkillers. Pfizer, the world's ...

BRISTOL, Tenn. — One day after Pfizer announced plans to buy King Pharmaceuticals this week, a class action lawsuit was filed to halt the acquisition, alleging King’s directors breached their ...

BRISTOL, Tenn. - A Maryland-based drug manufacturing firm run by the founders of King Pharmaceuticals has purchased the company's former Fifth Street location. UPM Pharmaceuticals announced Wednesday ...

NEW YORK (MarketWatch) -- King Pharmaceuticals Inc. Thursday agreed to purchase the rights to the Avinza pain treatment in the U.S., its territories and Canada from Ligand Pharmaceuticals for $265 ...

King Pharmaceuticals Inc. (KG) and partner Pain Therapeutics Inc. (PTIE) recently announced that they have resubmitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for ...

King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are ...

NEW YORK (CBS.MW) -- King Pharmaceuticals posted a second-quarter loss of $63.5 million, or 26 cents per share, that included a $65 million charge for a possible settlement with the Securities and ...